ClinicalTrials.gg
RecruitingNCT07284511TZPUpdated May 27, 2026

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

A Phase 2/3 interventional study of Tirzepatide and Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM) in Type 1 Diabetes, Type 1 Diabetes Mellitus and T1D, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 2/3, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre — 7 open to participants now, 7 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · McGill University Health Centre/Research Institute of the McGill University Health Centre.

Planned enrollment
2nd of 12
105 · median 34
Started
2026
with 1 other
Phase 2/3
5 of 15
4 open now
Registered
14th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 2/3, and was the 14th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

7 of the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, or all of them as a file.
02

Study summary

This research study is testing whether a weekly medication called tirzepatide can help adults with type 1 diabetes use their insulin pump more easily, specifically by reducing or eliminating the need to count carbohydrates at meals.

People with type 1 diabetes must take insulin for life, and even with advanced insulin pumps and continuous glucose monitors, many still struggle to keep blood sugar within the target range. One of the biggest challenges is carbohydrate counting, which requires estimating the amount of carbohydrates in every meal to give the correct insulin dose.

Tirzepatide is a medication currently approved for type 2 diabetes and weight management. Early research suggests it may also help people with type 1 diabetes by lowering appetite, slowing digestion, reducing insulin needs, and smoothing after-meal blood sugar rises.

This study will include 105 adults with type 1 diabetes at centers in Canada and Switzerland. Everyone will use the Tandem Control-IQ insulin pump with a Dexcom G7 continuous glucose monitor. Participants are randomly assigned to one of two groups:

Tirzepatide group:

Participants receive weekly tirzepatide injections. After the dose is gradually increased over 12 weeks, they will eventually try using their insulin pump without entering carbohydrate amounts at meals.

Control group:

Participants continue their usual therapy and keep counting carbohydrates for their mealtime insulin doses.

The main goal of the study is to learn whether people taking tirzepatide can safely maintain good blood sugar control without counting carbs, compared with standard care. All participants will attend several clinic visits and share their glucose, insulin, and health data throughout the 32-week trial. Some centers will also conduct heart/fitness, or body-composition tests.

As with any medication, tirzepatide may cause side effects such as nausea, vomiting, diarrhea, or decreased appetite. Rare but serious risks like gallbladder disease or pancreatitis are also monitored. Pregnancy must be avoided during the trial.

Overall, this study aims to understand whether adding tirzepatide to automated insulin delivery can simplify diabetes management, reduce burden, and maintain safe and effective glucose control for adults living with type 1 diabetes.

Read the detailed description

Current diabetes technology, including hybrid automated insulin delivery systems like the Tandem Control-IQ paired with the Dexcom G7 continuous glucose monitor, improves glucose control but still relies heavily on patients entering carbohydrate amounts before eating, a task that is difficult, error-prone, and often stressful.

Tirzepatide, which is approved for type 2 diabetes and weight management, works by slowing digestion, lowering appetite, reducing insulin requirements, and improving after-meal glucose spikes, and early evidence suggests it may offer similar benefits in type 1 diabetes. This study is designed to determine whether adding once-weekly tirzepatide injections to a commercially available automated insulin delivery system can make diabetes management easier for adults with type 1, particularly by reducing or eliminating the need to count carbohydrates at meals.

In this 32-week trial, 105 adults will be randomly assigned to receive tirzepatide or no tirzepatide while all participants use the Control-IQ system. Those receiving tirzepatide will gradually increase their dose over 12 weeks, continue counting carbohydrates until week 26, and then stop announcing meals entirely for the final 6 weeks, while the control group will count carbohydrates throughout.

Across the study, participants will attend scheduled clinic visits, complete remote follow-ups, undergo laboratory tests, and, depending on the site, may complete heart function tests, body-composition scans, fitness testing, or gastric emptying assessments. Researchers will compare glucose control, insulin needs, weight, metabolic markers, meal patterns, and patient-reported outcomes between groups, with the primary goal of determining whether glucose management without carbohydrate counting is not worse than (non-inferior to) standard carbohydrate counting.

The study also closely monitors safety, as tirzepatide can cause nausea, vomiting, diarrhea, decreased appetite, and rare complications such as gallbladder disease or pancreatitis. Overall, this research aims to learn whether combining tirzepatide with automated insulin delivery can safely simplify diabetes management, reduce treatment burden, and improve metabolic outcomes for adults living with type 1 diabetes.

03

Conditions studied

  • Type 1 Diabetes
  • Type 1 Diabetes Mellitus
  • T1D
  • T1DM
  • T1DM - Type 1 Diabetes Mellitus

Keywords

  • Type 1 Diabetes
  • Overweight or obesity in type 1 diabetes
  • Automated insulin delivery
  • Insulin pump
  • Continuous glucose monitoring
  • Tirzepatide
  • Mounjaro
  • GIP/GLP-1 receptor agonist
  • Dual incretin therapy
  • Adjunctive tirzepatide therapy
  • Tandem Control-IQ
  • Hybrid closed-loop system
  • Closed-loop insulin delivery
  • Dexcom G7
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Clinical diagnosis of type 1 diabetes for ≥ 1 year, per investigator judgment (confirmatory C-peptide and autoantibodies not required).
  • A ≥ 27 kg/m2.
  • > 6.5%, and \< 12%.
  • Current therapy: multiple daily injections or insulin pump.
  • Willingness to use Tandem Control IQ insulin pump system with the use of rapid or ultra rapid-acting insulins compatible with Tandem Control-IQ pump (e.g. Fiasp is not compatible)
  • Active carbohydrate counting for prandial insulin dosing.
  • Individuals of must be using or agree to use an effective birth-control method. Childbearing potential refers to participants of the female sex post-menarche who have not reached menopause and who do not have a medical condition causing sterility (e.g., hysterectomy). state refers to the absence of menses for 12 months without any alternative cause.

Exclusion criteria

Exclusion Criteria:

  • Use of GLP1-RAs within the last four weeks.
  • Use of antihyperglycemic agents other than insulin or metformin within the last 2 weeks.
  • Planned or ongoing pregnancy.
  • Breastfeeding.
  • Severe hypoglycemia requiring hospitalization in the past 2 months. Severe hypoglycemia is defined as requiring the assistance of another person, due to altered consciousness, to administer carbohydrates, glucagon, or other resuscitative actions.
  • Diabetic ketoacidosis within the last 2 months.
  • History of acute or chronic pancreatitis.
  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
  • Severe renal impairment with \<30 mL/min/1.73 m2 (CKD-EPI), measured within the last four months.
  • proliferative diabetic retinopathy or gastroparesis, as per the judgment of the investigator.
  • Current or ≤ 1 month use of supraphysiological doses of oral or intravenous .
  • History of bariatric surgery within the last 6 months.
  • Medical or psychiatric illness likely to interfere with participation (e.g. cirrhosis, active cancer, decompensated schizophrenia), per investigator judgment.
  • Inability or unwillingness to comply with safe diabetes management practices, in the view of the investigator.
  • Any safety concern that, in the investigator's judgment, precludes participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Tirzepatide group

    Participants randomized to this arm receive once-weekly subcutaneous tirzepatide in addition to use of the Tandem Control-IQ insulin pump and Dexcom G7 continuous glucose monitor. Tirzepatide is initiated at 2.5 mg weekly and increased by 2.5 mg every 4 weeks to a target dose of 10 mg weekly or the maximally tolerated dose. Dose escalation may be delayed or reduced if participants experience intolerable gastrointestinal symptoms. During Weeks 1-26, participants continue standard carbohydrate counting for all meals. Beginning in Week 27, participants stop entering carbohydrate amounts into the pump (no meal announcements) for six weeks while continuing tirzepatide at their maintenance dose. Throughout the intervention, participants undergo regular safety assessments, remote glucose data reviews, insulin-pump parameter adjustments as needed, and scheduled in-person visits to monitor metabolic, cardiovascular, and patient-reported outcomes.

    Drug: Tirzepatide · Device: Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM) · Behavioral: Carbohydrate Counting · Behavioral: No Meal Announcement

  • Active comparator
    Control group

    Participants randomized to the control arm use the Tandem Control-IQ automated insulin delivery system with the Dexcom G7 continuous glucose monitor, following standard-of-care diabetes management. They continue carbohydrate counting for all meals throughout the 32-week study and deliver prandial insulin boluses based on estimated carbohydrate intake, as is typical for users of hybrid closed-loop systems. No tirzepatide injections are administered. Participants receive the same device training, follow-up schedule, safety monitoring, glucose data reviews, and pump parameter adjustments as the tirzepatide arm. This arm serves as an active comparator, representing current standard therapy for type 1 diabetes with automated insulin delivery and meal announcements.

    Device: Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM) · Behavioral: Carbohydrate Counting

Interventions

  • Tirzepatide, administered as a once-weekly subcutaneous injection, initiated at 2.5 mg and escalated in 2.5-mg increments every 4 weeks to a target of 10 mg or the maximally tolerated dose, used as an adjunct therapy in adults with type 1 diabetes using the Tandem Control-IQ automated insulin delivery system.

    Also known as: Mounjaro

  • DeviceTandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM)

    This intervention uses the Tandem t:slim X2 insulin pump with the Control-IQ automated insulin delivery algorithm, integrated with the Dexcom G7 continuous glucose monitor. The system adjusts basal insulin and delivers automated correction boluses based on real-time glucose values. All participants receive standardized training and use this system for the full 32-week study. Rapid-acting insulin compatible with Control-IQ is required. This intervention is distinguished by its use under two different operational strategies: standard carbohydrate counting in the control arm and complete omission of meal announcements during the final 6 weeks in the tirzepatide arm.

    Also known as: Control-IQ, Dexcom G7

  • BehavioralCarbohydrate Counting

    Participants enter the estimated carbohydrate amount for every meal and snack into the Tandem Control-IQ insulin pump to calculate and deliver prandial insulin boluses. This reflects standard use of hybrid closed-loop systems. The procedure is maintained for the entire 32-week study in the control arm and during Weeks 1-26 in the tirzepatide arm.

    Also known as: Meal Announcement

  • BehavioralNo Meal Announcement

    Participants do not enter carbohydrate amounts or announce meals to the Tandem Control-IQ system. The pump operates without user-initiated prandial boluses, relying solely on automated basal adjustments and automated correction boluses. This intervention is implemented only in the tirzepatide arm during Weeks 27-32.

    Also known as: Omission of Carbohydrate Counting

06

What researchers measure

Primary outcomes

  1. Daytime Time-in-Range

    The primary outcome is the percentage of daytime hours (06:00-24:00) during which participants' glucose levels, measured by the Dexcom G7 continuous glucose monitor, fall within the target range of 3.9-10.0 mmol/L.

    Time frame: During the final 6 weeks of the study

Secondary outcomes

  1. Weight

    Change in body weight to assess the effects of tirzepatide on body composition. Weight is measured in kilograms.

    Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study

  2. Height

    Change in height to assess the effects of tirzepatide on body composition. Height is measured in meters.

    Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.

  3. Body Mass Index

    Change in BMI to assess the effects of tirzepatide on body composition. BMI is measured in kilograms per square meter.

    Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study

  4. Waist circumference

    Change in waist circumference to assess the effects of tirzepatide on body composition. Waist circumference is measured in centimetres.

    Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study

  5. Waist-to-Hip Ratio

    Change in waist-to-hip ratio to assess the effects of tirzepatide on body composition. Waist-to-Hip Ratio is measured by dividing the waist circumference by the hip circumference. It is unitless.

    Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.

  6. Systolic Blood Pressure

    Change in systolic blood pressure to evaluate the cardiovascular effects of tirzepatide. Systolic blood pressure is measured in millimetres of mercury.

    Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.

  7. Diastolic Blood Pressure

    Change in diastolic blood pressure to evaluate the cardiovascular effects of tirzepatide. Diastolic blood pressure is measured in millimetres of mercury.

    Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.

  8. Resting Heart Rate

    Change in resting heart rate to assess the cardiovascular effects of tirzepatide. Resting heart rate is measured in beats per minute.

    Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.

  9. Insulin-related measures

    Daily insulin requirements, including basal insulin, bolus insulin, and total insulin units per day, recorded through the insulin pump. Total insulin use normalized to body weight (units/kg/day) to assess treatment-related changes in insulin sensitivity. Carbohydrate amounts entered for bolus dosing (control arm and Weeks 1-26 of tirzepatide arm).

    Time frame: Continuously from randomization through Week 32, with primary analysis focused on Weeks 27-32, At Week 8 and Week 16 post-study.

  10. Glucose outcomes

    Percentage of CGM readings within 3.9-10.0 mmol/L, 3.9-7.8 mmol/L, \<3.9 mmol/L, \<3.0 mmol/L, \>10.0 mmol/L, and \>13.9 mmol/L, as well as mean glucose, glucose standard deviation, and glucose coefficient of variation.

    Time frame: Continuously collected from randomization through Week 32, with key comparisons during Weeks 23-26 and Weeks 27-32, At Week 8 and Week 16 post-study.

  11. Glycated Hemoglobin (HbA1c)

    Change in glycated hemoglobin (HbA1c) to assess overall glycemic control over the study period.

    Time frame: At enrollment, mid-study at Week 16, and at the end-of-study visit at Week 32, At Week 8 and Week 16 post-study.

  12. Estimated Glomerular Filtration Rate

    Changes in estimated glomerular filtration rate. eGFR is measured in millilitres/minute/body surface.

    Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.

  13. Serum Creatinine

    Changes in serum creatinine. Serum creatinine is measured in umol/L.

    Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.

  14. Albumin-to-Creatinine Ratio

    Changes in urinary albumin-to-creatinine ratio. Urinary albumin-to-creatinine ratio is measured in mg/mmol.

    Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.

  15. Lipid Panel (Total Cholesterol, LDL-C, HDL-C, Triglycerides)

    Changes in fasting lipid profile to assess cardiometabolic effects of tirzepatide. All components of the lipid panel are measured in millimole/liter.

    Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.

  16. Liver Function Markers (Alanine transaminase, Alkaline phosphatase)

    Changes in liver enzymes to monitor hepatic safety. Hepatic enzymes are measured in Units per Litre.

    Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.

  17. Liver Function Markers (Bilirubin)

    Changes in bilirubin to monitor hepatic safety. Bilirubin (Total, Direct, Indirect) are measured in micromoles per litre.

    Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.

  18. Cardiac Biomarkers (NT-proBNP)

    Serum biomarker used to assess cardiac strain, providing insights into the broader metabolic effects of tirzepatide. NT-proBNP is measured in picograms per millilitre.

    Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.

  19. Inflammatory Biomarkers (hs-CRP)

    Serum biomarkers used to assess inflammation providing insights into the broader metabolic effects of tirzepatide. hs-CRP is measured in milligrams per litre.

    Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.

  20. Inflammatory Biomarkers (IL-6)

    Serum biomarkers used to assess inflammation, providing insights into the broader metabolic effects of tirzepatide. IL-6 is measured in picograms per millilitre.

    Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.

  21. C-Peptide

    Change in fasting C-peptide to assess residual β-cell function.

    Time frame: At enrollment and at Week 32, At Week 8 and Week 16 post-study.

  22. Carotid-Femoral Pulse Wave Velocity and Pulse Wave Analysis

    Measures of arterial stiffness and central blood pressure, used to evaluate vascular effects of treatment.

    Time frame: At enrollment and at Week 32 (site-dependent).

  23. DXA Body Composition

    Whole-body DXA assessment of fat mass, lean mass, visceral fat, and bone density.

    Time frame: At enrollment and at Week 32 (site-dependent).

  24. Echocardiogram (Diastolic Function Parameters)

    Assessment of cardiac structure and diastolic function, including E/A ratio, e', E/e', and left atrial volume.

    Time frame: At enrollment and at Week 32 (site-dependent).

  25. VO₂-max Test

    Measurement of maximal oxygen consumption to evaluate cardiopulmonary fitness.

    Time frame: At enrollment and at Week 32 (site-dependent).

  26. Quality-of-Life Measures (Diabetes Distress Scale)

    Changes in the standardized Diabetes Distress Scale using the validated questionnaire. A participant's score is measured as the sum of responses to the appropriate items divided by the number of items in that scale. A mean item score 2.0 - 2.9 is considered moderate distress, and a mean item score \> 3.0 is considered high distress.

    Time frame: At enrollment and at Week 32.

  27. Quality-of-Life Measures (Hypoglycemia Fear Survey II)

    Changes in the standardized Hypoglycemia Fear Survey II using the validated questionnaire. HFS-II Total Score range: 0-132. Higher scores on the total HFS-II indicate a greater fear of hypoglycemia. The questionnaire does not have pre-defined cut-off scores for diagnostic categories; instead, the scores are used to measure the level of fear.

    Time frame: At enrollment and at Week 32.

  28. Quality-of-Life Measures (Three Factor Eating r18 Questionnaire)

    Changes in the standardized Three Factor Eating Questionnaire scores. The three-factor eating questionnaire provides a score from 0 to 100 for cognitive restraint, uncontrolled eating, and emotional eating. Higher scores indicate greater cognitive restraint, uncontrolled eating, and emotional eating.

    Time frame: At enrollment and at Week 32.

  29. Gastric Emptying via [13C] Acetate Breath Test

    Rate of gastric emptying assessed by breath ¹³CO₂ appearance following standardized test meal.

    Time frame: At enrollment (or training visit) and at Week 32 (site-dependent).

  30. Blood Glucagon Response to Standardized Meal

    Change in glucagon concentrations following ingestion of a standardized liquid meal.

    Time frame: At enrollment and at Week 32 (site-dependent).

  31. Meal Tracking Using Keenoa or MyFood24

    Assessment of caloric intake and macronutrient composition via 3-day dietary records.

    Time frame: Prior to randomization, during Week 16, and during Week 32.

Other outcomes

  1. Severe hypoglycemia

    Episode requiring the assistance of another person, due to altered consciousness, to administer carbohydrates, glucagon, or other resuscitative actions.

    Time frame: From the time the participant signs informed consent until the end of study participation at Week 32, with additional safety follow-up at Week 8 and Week 16 post-study.

  2. Diabetic Ketoacidosis

    Clinical episode characterized by hyperglycemia/euglycemia, ketonemia or ketonuria, metabolic acidosis, and associated symptoms such as nausea, vomiting, abdominal pain, rapid breathing, or altered consciousness. Events requiring emergency evaluation, intravenous fluids, or hospital treatment will be recorded as DKA. All episodes will be assessed for severity, timing, precipitating factors, and their relationship to study interventions, including tirzepatide use and automated insulin delivery performance.

    Time frame: From the time the participant signs informed consent until the end of study participation at Week 32, with additional safety follow-up at Week 8 and Week 16 post-study.

  3. Gastrointestinal and related side effects

    Nausea Vomiting Abdominal pain Diarrhea Constipation Liver profile changes Gallbladder disease Acute pancreatitis Other related side effects

    Time frame: From the time the participant signs informed consent until the end of study participation at Week 32, with additional safety follow-up at Week 8 and Week 16 post-study.

07

Study locations

1 of 4 sites recruiting
  • Institut de Recherches Cliniques de Montréal
    Montreal, Quebec H2W 1R7, Canada
    Not yet recruiting
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
    • Keddy Moise, MSc (candidate) · Contactkeddy.moise@mail.mcgill.ca · 438-531-6896
    • Rebecca Boyer-Hernandez, BSc. · Contactrebecca.boyer-hernandez@affiliate.mcgill.ca · 514-318-7298
    • Melissa-Rosina Pasqua, MD, PhD · Principal investigator
    • Michael A Tsoukas, MD · Sub investigator
    • Abhinav Sharma, MD · Sub investigator
    • Natasha Garfield, MD · Sub investigator
    • Ahmad Haidar, PhD · Sub investigator
  • Hygea Medical Clinic
    Montreal, Quebec H4A 3T2, Canada
    Recruiting
  • Insel Hospital, University Hospital Bern
    Bern, 3010, Switzerland
    Not yet recruiting
08

References and documents

Publications

  • Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. PubMed 27633186 ↗
  • Karlsson J, Persson LO, Sjostrom L, Sullivan M. Psychometric properties and factor structure of the Three-Factor Eating Questionnaire (TFEQ) in obese men and women. Results from the Swedish Obese Subjects (SOS) study. Int J Obes Relat Metab Disord. 2000 Dec;24(12):1715-25. doi: 10.1038/sj.ijo.0801442. PubMed 11126230 ↗
  • Saisho Y. Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes. Int J Environ Res Public Health. 2018 May 9;15(5):947. doi: 10.3390/ijerph15050947. PubMed 29747423 ↗
  • Gonder-Frederick LA, Schmidt KM, Vajda KA, Greear ML, Singh H, Shepard JA, Cox DJ. Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes. Diabetes Care. 2011 Apr;34(4):801-6. doi: 10.2337/dc10-1343. Epub 2011 Feb 23. PubMed 21346182 ↗
  • Fisher L, Hessler D, Polonsky W, Strycker L, Masharani U, Peters A. Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. J Diabetes Complications. 2016 Aug;30(6):1123-8. doi: 10.1016/j.jdiacomp.2016.03.032. Epub 2016 Apr 4. PubMed 27118163 ↗
  • Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PubMed 34170647 ↗
  • Martin C, Ravussin E, Sanchez-Delgado G, Nishiyama H, Li J, Urva S, et al. The effect of tirzepatide during weight loss on food intake, appetite, food preference and food craving in people with obesity. Can J Diabetes. 2023 Jul;47(7 Suppl):S199. doi:10.1016/j.jcjd.2023.10.370
  • Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 Jan;27(1):1-9. doi: 10.1089/dia.2024.0328. Epub 2025 Jan 2. PubMed 39745353 ↗
  • Pasqua MR, Tsoukas MA, Kobayati A, Aboznadah W, Jafar A, Haidar A. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat Med. 2025 Apr;31(4):1239-1245. doi: 10.1038/s41591-024-03463-z. Epub 2025 Jan 10. PubMed 39794615 ↗
  • Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018 Feb;41(2):258-266. doi: 10.2337/dc17-0417. Epub 2017 Dec 15. PubMed 29246950 ↗
  • Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Verges B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020 Apr;46(2):100-109. doi: 10.1016/j.diabet.2019.101117. Epub 2019 Sep 17. PubMed 31539622 ↗
  • Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. PubMed 31189511 ↗
  • Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. PubMed 27295427 ↗
  • Tsoukas MA, Cohen E, Legault L, von Oettingen JE, Yale JF, Vallis M, Odabassian M, El Fathi A, Rutkowski J, Jafar A, Ghanbari M, Gouchie-Provencher N, Rene J, Palisaitis E, Haidar A. Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies. Diabetes Obes Metab. 2021 Sep;23(9):2090-2098. doi: 10.1111/dom.14447. Epub 2021 Jun 21. PubMed 34047449 ↗
  • Karakus KE, Klein MP, Akturk HK, Shah VN. Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ. Diabetes Ther. 2024 Jul;15(7):1647-1655. doi: 10.1007/s13300-024-01592-9. Epub 2024 May 14. PubMed 38743306 ↗
  • Rivera Gutierrez R, Tama E, Bechenati D, Castaneda Hernandez R, Bennett PK, McNally AW, Fansa S, Anazco D, Acosta A, Hurtado Andrade MD. Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity. Mayo Clin Proc. 2025 Feb;100(2):265-275. doi: 10.1016/j.mayocp.2024.07.006. Epub 2024 Nov 26. PubMed 39601745 ↗
  • Templer S. Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions. Front Endocrinol (Lausanne). 2022 Jun 6;13:919942. doi: 10.3389/fendo.2022.919942. eCollection 2022. PubMed 35733769 ↗
  • Meade LT, Rushton WE. Accuracy of Carbohydrate Counting in Adults. Clin Diabetes. 2016 Jul;34(3):142-7. doi: 10.2337/diaclin.34.3.142. PubMed 27621531 ↗
  • Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008 May;31(5):934-9. doi: 10.2337/dc07-1967. Epub 2008 Feb 5. PubMed 18252903 ↗
  • Peacock S, Frizelle I, Hussain S. A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Ther. 2023 May;14(5):839-855. doi: 10.1007/s13300-023-01394-5. Epub 2023 Apr 5. PubMed 37017916 ↗
  • Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019 Feb;21(2):66-72. doi: 10.1089/dia.2018.0384. Epub 2019 Jan 18. PubMed 30657336 ↗
  • Janez A, Guja C, Mitrakou A, Lalic N, Tankova T, Czupryniak L, Tabak AG, Prazny M, Martinka E, Smircic-Duvnjak L. Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review. Diabetes Ther. 2020 Feb;11(2):387-409. doi: 10.1007/s13300-019-00743-7. Epub 2020 Jan 4. PubMed 31902063 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data may be shared with qualified researchers after completion of the trial and publication of the primary results. Shared data may include de-identified demographic variables, glucose and insulin delivery data, laboratory results, questionnaire scores, and device-based assessments collected during the study. All data will be reviewed to minimize re-identification risk in accordance with Canadian and Swiss privacy regulations. Researchers must submit a scientifically valid proposal and sign a data use agreement. Requests will be reviewed by the study team, and approved data will be provided through a secure transfer process.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: IPD will be made available beginning 12 months after publication of the primary results and for a period of five years thereafter.

Access criteria: Researchers must submit a scientifically valid proposal and sign a data use agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2028, 20 months after the start.

Of 19 phase 2/3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 16, 2025
StartActual
May 19, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2029
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07284511
Collaborators
Breakthrough T1D, Institut de Recherches Cliniques de Montreal, Insel Gruppe AG, University Hospital Bern
Responsible party
Melissa-Rosina Pasqua (Assistant Professor, Division of Endocrinology and Metabolism, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Dec 16, 2025
Start date
May 19, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
May 27, 2026

Study contacts

Keddy Moise, MSc (candidate)
Contact
keddy.moise@mail.mcgill.ca
438-531-6896
Rebecca Boyer-Hernandez, BSc
Contact
rebecca.boyer-hernandez@affiliate.mcgill.ca
Melissa-Rosina Pasqua, MD, PhD
principal investigator · McGill University Health Centre/Research Institute of the McGill University Health Centre
Ahmad Haidar, PhD
study director · McGill University Health Centre/Research Institute of the McGill University Health Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion